Copenhagen, May 22, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL), a biotechnology company changing lives with innovative peptide-based medicines, today announced that the U.S. Food and Drug Administration (FDA) has…Original Article
Zealand Pharma Announces FDA acceptance of New Drug Application for the Dasiglucagon HypoPal® Rescue Pen for Treatment of Severe Hypoglycemia
